Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis

Abstract

IntroductionAdalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation. The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle, versus the current 40 mg/0.8 mL formulation in patients with rheumatoid arthritis (RA).MethodsTwo identically designed, phase 2, randomized, single-blind, two-period crossover studies were conducted in Belgium and the Czech Republic (Study 1) and Australia, Canada, and Germany (Study 2). In both studies, adults with RA [biologic-naive or current users of 40 mg/0.8 mL adalimumab with an average injection site-related pain rating ≥3 cm on a visual analog scale (VAS; 0–10 cm)] were randomized to receive 40 mg/0.8 mL or 40 mg/0.4 mL adalimumab at visit 1. After 1–2 weeks (depending on patient medication schedule), patients received the other formulation at visit 2. A pain VAS [McGill Pain Questionnaire (MPQ-SF)] and the Draize scale were evaluated immediately after injection and 15 min postinjection. The primary endpoint was immediate pain after injection.Results64 and 61 patients were randomized in Studies 1 and 2, respectively. Both studies found a clinically relevant and statistically significant lower immediate pain after injection for the 40 mg/0.4 mL versus the 40 mg/0.8 mL formulation. The mean difference on the VAS for the pooled data (−2.48 cm) was also clinically relevant. Most other endpoints in both studies favored the 40 mg/0.4 mL formulation, and its tolerability and safety profile were consistent with 40 mg/0.8 mL adalimumab.ConclusionA 40 mg/0.4 mL adalimumab formulation was well tolerated and associated with less injection site-related pain than the 40 mg/0.8 mL adalimumab formulation.Trial registrationClinicalTrials.gov identifier, NCT01561313 and NCT01502423.FundingAbbVie.Electronic supplementary materialThe online version of this article (doi:10.1007/s40744-016-0041-3) contains supplementary material, which is available to authorized users.

Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

“…Evidence to support the use of premedication with corticosteroids or antihistamines is limited, with patients still experiencing infusion reactions despite premedication and therefore should be considered on an individual basis. Injection site pain due to adalimumab can be reduced by using low volume formulations which are free from citrate buffers, with no change in efficacy …”

Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review

“…Of note, any variations in ISP between originator and biosimilar biologics do not appear to reflect any differences in immunogenicity between these agents [23], with biosimilars reported to be effective and well tolerated in maintaining complete remission after the switch from the originator agent [24,25]. pH Bunke et al [26] suggested that the difference between the physiological pH of the tissue at Table 1 Factors contributing to subcutaneous injection-site pain Product-related factors Injection-related factors Patient-related factors • Formulation (ingredients, pH, buffers) [16,17,27,28,40] • Delivery volume [15,[32][33][34] • Needle gauge size [44] • Device type [49][50][51][52][53][54] • Injection speed [55][56][57][58] • Fluid viscosity [55] • Injection angle/technique [59,60] • Temperature of product [62,63] • Allergens [65,66] • Injection frequency [61] • Injection site [35] • Low body weight [68] • Injection anxiety/'needle phobia' [69,70] • Pain catastrophising [72] • Nocebo effect [73,74] • Female gender [67] • Fibromya...…”

Classification and mitigation of negative injection experiences with biologic medications

“…Citrate‐free adalimumab was associated with a 54% mean reduction in pain compared to the standard formulation (Nash et al, ). Potential explanations for less pain with the citrate‐free formulation include use of a thinner needle (29 vs 27 G), 50% less volume for the same dose, and removal of the sodium citrate buffer (Abbvie, ; Nash et al, ). Citrate‐free adalimumab can be administered with an autoinjector and may serve patients who experience severe injection pain.…”